Quality indicators in radiotherapy.

PubWeight™: 1.08‹?› | Rank: Top 10%

🔗 View Article (PMID 17267059)

Published in Radiother Oncol on January 30, 2007

Authors

Luca Cionini1, Gianstefano Gardani, Pietro Gabriele, Secondo Magri, Pier Luigi Morosini, Antonella Rosi, Vincenza Viti, Italian Working Group General Indicators

Author Affiliations

1: Dipartimento di Oncologia, Az. Ospedaliera Pisana-Università degli Studi, Pisa, Italy.

Articles by these authors

Does tumor growth follow a "universal law"? J Theor Biol (2003) 2.47

Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst (2011) 2.47

Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol (2006) 1.45

Validation of the Italian version of the "Mood Disorder Questionnaire" for the screening of bipolar disorders. Clin Pract Epidemiol Ment Health (2005) 1.29

The use of antidepressant drugs and the lifetime prevalence of major depressive disorders in Italy. Clin Pract Epidemiol Ment Health (2010) 1.20

Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol (2008) 1.20

Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. Cancer (2012) 1.18

The accuracy of the Italian version of the Hypomania Checklist (HCL-32) for the screening of bipolar disorders and comparison with the Mood Disorder Questionnaire (MDQ) in a clinical sample. Clin Pract Epidemiol Ment Health (2006) 1.13

Emptying the rectum before treatment delivery limits the variations of rectal dose - volume parameters during 3DCRT of prostate cancer. Radiother Oncol (2006) 1.08

The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia. Curr Opin Psychiatry (2008) 1.08

Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: results of a large multicenter observational study. Radiother Oncol (2009) 1.06

Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study. Int J Radiat Oncol Biol Phys (2005) 0.98

Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism. Cancer Res (2003) 0.96

Response to neoadjuvant therapy in locally advanced rectal cancer: assessment with diffusion-weighted MR imaging and 18FDG PET/CT. Abdom Imaging (2012) 0.90

Accessibility as a major determinant of radiotherapy underutilization: a population based study. Health Policy (2006) 0.90

Change in glucose metabolism measured by 18F-FDG PET/CT as a predictor of histopathologic response to neoadjuvant treatment in rectal cancer. Abdom Imaging (2011) 0.90

Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carboplatin + taxol in locally advanced nasopharyngeal carcinoma. Cancer Chemother Pharmacol (2010) 0.90

Comparative evaluation of CT-based and respiratory-gated PET/CT-based planning target volume (PTV) in the definition of radiation treatment planning in lung cancer: preliminary results. Eur J Nucl Med Mol Imaging (2013) 0.89

Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma. Med Oncol (2003) 0.88

Surgery and radiotherapy in the treatment of malignant parotid tumors: a retrospective multicenter study. Tumori (2009) 0.88

Is it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome. Int J Radiat Oncol Biol Phys (2011) 0.87

Laparotomy wound recurrence of endometrial carcinoma. Gynecol Oncol (2003) 0.87

1H NMR detects different metabolic profiles in glioblastoma stem-like cells. NMR Biomed (2013) 0.86

Clinical and biological prognostic factors in 179 cases with sinonasal carcinoma treated in the Italian Piedmont region. Oncology (2009) 0.85

Chondrosarcoma of the nasal septum. Eur Arch Otorhinolaryngol (2014) 0.84

External beam radiotherapy plus high-dose-rate brachytherapy for treatment of locally advanced prostate cancer: the initial experience of the Catalan Institute of Oncology. Brachytherapy (2009) 0.83

Role of glutathione in apoptosis induced by radiation as determined by 1H MR spectra of cultured tumor cells. Radiat Res (2007) 0.83

Increasing the risk of late rectal bleeding after high-dose radiotherapy for prostate cancer: the case of previous abdominal surgery. Results from a prospective trial. Radiother Oncol (2012) 0.83

(1H) MRS studies of signals from mobile lipids and from lipid metabolites: comparison of the behavior in cultured tumor cells and in spheroids. NMR Biomed (2004) 0.83

Impact of the radiotherapy technique on the correlation between dose-volume histograms of the bladder wall defined on MRI imaging and dose-volume/surface histograms in prostate cancer patients. Phys Med Biol (2013) 0.82

Characterization of 1H NMR detectable mobile lipids in cells from human adenocarcinomas. FEBS J (2009) 0.82

Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART). Med Oncol (2013) 0.81

Clinical and technical feasibility of ultra-boost irradiation in Dominant Intraprostatic Lesion by Tomotherapy: preliminary experience and revision of literature. Panminerva Med (2015) 0.81

Quality assurance of a record-and-verify system. Tumori (2009) 0.80

Epirubicin-vinorelbine intravenous combination followed by oral vinorelbine as first-line treatment in metastatic breast cancer. Tumori (2008) 0.80

Identification of amide protons of glutathione in MR spectra of tumour cells. NMR Biomed (2008) 0.79

Irradiation of pacemakers and cardio-defibrillators in patients submitted to radiotherapy: a clinical experience. Tumori (2010) 0.79

Carboplatin plus taxol is an effective third-line regimen in recurrent undifferentiated nasopharyngeal carcinoma. Tumori (2002) 0.78

Paclitaxel and carboplatin in neo-adjuvant and concomitant chemoradiotherapy in locally advanced head and neck squamous cell carcinoma. Tumori (2003) 0.78

Impact of age at diagnosis on overall and disease-free survival in men with prostate cancer following conformal 3D radiation therapy. Tumori (2012) 0.78

Prostate image-guided radiotherapy by megavolt cone-beam CT. Strahlenther Onkol (2011) 0.78

Dose to organs at risk in the upper abdomen in patients treated with extended fields by helical tomotherapy: a dosimetric and clinical preliminary study. Radiat Oncol (2013) 0.77

Clinical application and dosimetric calibration procedure of the superficial and orthovoltage therapy unit Therapax DXT300. Tumori (2002) 0.77

Glycosidic intermediates identified in 1H MR spectra of intact tumour cells may contribute to the clarification of aspects of glycosylation pathways. NMR Biomed (2011) 0.77

Quality assurance of 3D-CRT: indications and difficulties in their applications. Crit Rev Oncol Hematol (2008) 0.77

Changes in patterns of practice for prostate cancer radiotherapy in Italy 1995-2003. A survey of the Prostate Cancer Study Group of the Italian Radiation Oncology Society. Tumori (2014) 0.77

(1)H-MRS can detect aberrant glycosylation in tumour cells: a study of the HeLa cell line. NMR Biomed (2011) 0.77

Radiotherapy after partial laryngectomy: an analysis of 36 cases and a proposal to optimize radiotherapy. Tumori (2009) 0.77

Salvage external beam radiotherapy for recurrent prostate adenocarcinoma after high-intensity focused ultrasound as primary treatment. Urol Int (2013) 0.77

Psychooncology and cancer progression-related alterations of pleasure-associated neurochemical system: Abnormal neuroendocrine response to apomorphine in advanced cancer patients. Neuro Endocrinol Lett (2003) 0.76

Gemcitabine and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. Anticancer Res (2003) 0.76

Comparison of endorectal magnetic resonance imaging, clinical prognostic factors and nomograms in the local staging of prostate cancer patients treated with radiotherapy. Tumori (2008) 0.76

External beam radiotherapy with dose escalation in 1080 prostate cancer patients: definitive outcome and dose impact. Panminerva Med (2016) 0.75

Endocrine effects of erythropoietin in cancer patients. Hematology (2005) 0.75

(1) H NMR spectroscopy of glioblastoma stem-like cells identifies alpha-aminoadipate as a marker of tumor aggressiveness. NMR Biomed (2015) 0.75

Technical and clinical description of a case of extensive anogenital Paget's disease associated with anal cancer treated by tomotherapy. Tumori (2014) 0.75

Percentage of positive prostate biopsies independently predicts biochemical outcome following radiation therapy for prostate cancer. Panminerva Med (2015) 0.75

Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients. Neuro Endocrinol Lett (2002) 0.75

Italian survey in postoperative radiation therapy for prostate carcinoma by the AIRO National Working Group on Prostate Radiotherapy: definitive results. Tumori (2005) 0.75

Radiotherapy alone or with concomitant daily low-dose carboplatin in locally advanced, unresectable head and neck cancer: definitive results of a phase III study with a follow-up period of up to ten years. Tumori (2010) 0.75

Effects of IL-2 preoperative immunotherapy on surgery-induced changes in angiogenic regulation and its prevention of VEGF increase and IL-12 decline. Hepatogastroenterology (2002) 0.75

Hereditary paraganglioma syndrome associated with SDHD gene mutations: a patient with multicentric presentation treated with radiotherapy. Case report. Tumori (2011) 0.75